Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Sihang Dong, Shuang Wu, Ke Liang, Hui Zhang, Fangzheng Guo, et al.
…URPOSE:** The only World Health Organization (WHO)-approved vaccine for tuberculosis (TB), Bacillus Calmette-Guérin (BCG), shows limited efficacy, particularly against adult pulmonary TB. Moreover, traditional subunit vaccines often suffer from poor immunogenicity. To addres…
Bhaskar A, Pahuja I, Negi K, Verma A, Ghoshal A, et al.
Bacille Calmette-Guerin (BCG) generates limited long-lasting adaptive memory responses leading to short-lived protection against adult pulmonary tuberculosis (TB). Here, we show that host sirtuin 2 (SIRT2) inhibition by AGK2 significantly enhances the BCG vaccine efficacy during …
Mustafa AD, Kalyanasundram J, Sabidi S, Song AA, Abdullah M, et al.
…ng prevented and controlled by the Bacille Calmette Guérin (BCG) vaccine, the protective efficacy is highly variable and substandard (0-80%) in adults. Therefore, novel and effective tuberculosis vaccine that can overcome the limitations from BCG vaccine need to be developed. Res…
Yuqin Xue, Chao Fan, Yun Huang, Ying Jin, Yijing Zheng, et al.
…, as the currently available Bacillus Calmette-Guérin (BCG) vaccine provides only limited protection against adult pulmonary TB. This study aimed to develop and evaluate a novel fusion vaccine that combines the safety of BCG, the broader antigenic repertoire of Mycobacterium…
Zhuang Li, Yilu Zhao, Ling Yang, Linsheng Li, Zhaoyang Ye, et al.
…vent and control TB, the existing Bacillus Calmette–Guérin (BCG) vaccine exhibits limited protective efficacy in adult pulmonary TB. Therefore, developing a novel TB vaccine is an urgent need. This study designed a novel multi-epitope vaccine (MEV) to combat MTB infection, utiliz…
Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, et al.
Background Bacille Calmette-Guérin (BCG), the live attenuated tuberculosis vaccine, is manufactured under different conditions across the globe generating formulations that may differ in clinical efficacy. Innate immune recognition of live BCG contributes to immunogenicity sugges…
Craig SR, Lahey T, Dixit A, Fordham von Reyn C
Background The current vaccine against tuberculosis, BCG, is effective when given in most TB-endemic countries at birth but has diminished efficacy against pulmonary TB after 15-20 years. As a result, new booster vaccines for adolescents and adults are being developed to realize …
Song D, Ji J, Yang S, Chen Z, Liu J, et al.
…s, remains a major global public health threat. The limited efficacy of the current Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary TB highlights the urgent need for improved vaccine strategies. To address this, we engineered a recombinant BCG strain, designated rB…
Mingming Zhang, Syed Luqman Ali, Yuan Tian, Aigul Abduldayeva, Shuang Zhou, et al.
…TB) remains a pressing global health crisis. The inadequate efficacy of the BCG vaccine against adult pulmonary TB underscores the urgent need for novel, effective vaccines. This study aimed to design a novel mRNA vaccine candidate against TB using a rational immunoinformatics ap…
Singh AK, Srikrishna G, Bivalacqua TJ, Bishai WR
Bacillus Calmette-Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global…
Weng CH, Saal A, Butt WW, Bica N, Fisher JQ, et al.
…ited data on effective therapies. Bacillus Calmette-Guérin (BCG) vaccine, a live-attenuated strain derived from an isolate of Mycobacterium bovis and originally designed to prevent tuberculosis, has shown some efficacy against infection with unrelated pathogens. In this study, we…
Lázaro M Marques-Neto, Monalisa M Trentini, Ana Carolina R Moreno, Silas F Eto, Ana Carolina O Carvalho, et al.
… remains a global public health challenge, with the current BCG vaccine providing limited efficacy in adults, and available treatments being lengthy and debilitating. To overcome these challenges, we have previously developed a recombinant BCG strain expressing the detoxifiedHeat…
Szachniewicz MM, van den Eeden SJF, van Meijgaarden KE, Franken KLMC, van Veen S, et al.
…nd a quarter of the global population. The sole licensed TB vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), shows variable efficacy, particularly among adolescents and adults, underscoring the pressing need for more effective vaccination strategies. The administratio…
Dongmei Song, Jing Ji, Shuo Yang, Zhaohang Chen, Jiahe Liu, et al.
…s, remains a major global public health threat. The limited efficacy of the current Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary TB highlights the urgent need for improved vaccine strategies. To address this, we engineered a recombinant BCG strain, designat…
Feng Shan, Andrew Simonson, Joshua D. Bromley, Michael C. Chao, Doaa Megahed, et al.
Abstract Description Background The limited efficacy of the BCG vaccine for adult pulmonary Tuberculosis (TB), as well as rising drug resistance, underscores the need for new vaccines and treatments. Concomitant immunity provides strong protection against M. tuberculosis (Mtb) re…
Davood Mansury, Kiarash Ghazvini, Saeid Amel Jamehdar, Ali Badiee, Mohsen Tafaghodi, et al.
BACKGROUND: Due to the ineffectiveness of the BCG vaccine, especially in adult pulmonary tuberculosis (TB), and variable efficacies against childhood forms of TB, developing an effective TB vaccine is a major priority in controlling this disease. The aim of this study was to eval…
Mansury D, Ghazvini K, Amel Jamehdar S, Badiee A, Tafaghodi M, et al.
Background Due to the ineffectiveness of the BCG vaccine, especially in adult pulmonary tuberculosis (TB), and variable efficacies against childhood forms of TB, developing an effective TB vaccine is a major priority in controlling this disease. The aim of this study was to evalu…
Gong W, Pan C, Cheng P, Wang J, Zhao G, et al.
…d the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accum…
Yongqiang Li, Xiuping Jia, Jinhua Tang, Huilian Qiao, Jiani Zhou, et al.
…osis (TB) is a major global health threat, with the current(BCG) vaccine having limited efficacy against adult pulmonary disease. Trained immunity (TI) is a form of innate immune memory that enhances antimicrobial defense. It is characterized by the epigenetic and metabolic repro…
Khoshnood S, Heidary M, Haeili M, Drancourt M, Darban-Sarokhalil D, et al.
…among people with HIV in 2016. The Bacille Calmette-Guerin (BCG) is the only available TB vaccine which fails to provide consistent protection against pulmonary TB in adults and adolescents despite being efficacious at protecting infants and young children from the most severe, o…
Eunkyung Shin, Jin-Seung Yun, Young-Ran Lee, Hye-Ran Cha, Soo-Min Kim, et al.
…on deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults. In this study, we constructed a recombinant vaccinia virus expressing Ag85B from M. tuberculosis using a…
Kirk NM, Huang Q, Vrba S, Rahman M, Block AM, et al.
…b) remains a major global health threat. The only available vaccine Bacille Calmette-Guérin (BCG) does not prevent adult pulmonary TB. New effective TB vaccines should aim to stimulate robust T cell responses in the lung mucosa to achieve high protective efficacy. We have previou…
Kaviya Parambath Kootery, Suma Sarojini
… pathogens. We have only a few protective shields, like the BCG vaccine against the pathogen, which itself has poor efficacy in preventing adult tuberculosis. Even though different vaccine trials for an alternative vaccine have been conducted, those studies have not shown much pr…
Sarman Singh
…f Lancet Infectious Diseases focusing on TB control through vaccine is worth reading [5]. The editorial very aptly mentions that the COVID-19 epidemic has taught us its negative as well as positive sides. On one hand, TB case detection rates were compromised due to a shift of man…
Mukherjee N, Julián E, Torrelles JB, Svatek RS
The Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine was generated in 1921 with the efforts of a team of investigators, Albert Calmette and Camille Guérin, dedicated to the determination to develop a vaccine against active tuberculosis (TB) disease. Since then, BCG v…